Update on raloxifene to prevent endometrial-breast cancer

European Journal of Cancer

Volumn 36, Issue SUPPL. 4, 2000, Pages 54-56

  Goldstein, S R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast Cancer; Endometrial Cancer; Raloxifene; SERMs; Sonohysterography; Tamoxifen; Transvaginal ultrasound

Indexed keywords

DROLOXIFENE; IDOXIFENE; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DRUG SAFETY; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; HUMAN; HYSTEROGRAPHY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; SECOND CANCER; TRANSVAGINAL ECHOGRAPHY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 0033753493     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00227-6     Document Type: Article

References (10)

1. Tamoxifen and endometrial cancer
2. Hysteroscopic follow-up during tamoxifen treatment
3. Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding
4. Unusual ultrasound appearance of the uterus in patients receiving tamoxifen
5. Uterine safety considerations for selective estrogen receptor modulators
6. Effect of raloxifene, estrogen, and placebo on the postmenopausal endometrium: A 12 month comparative study
7. The effect of raloxifene on risk of breast cancer in postmenopausal women, results from the MORE randomized trial
8. Distinct effects of selective estrogen receptor modulators on estrogen dependent and estrogen independent human breast cancer cell proliferation
9. Selective estrogen receptor modulators and postmenopausal women's health